AFFILIATIONS
1 The First Affliated Hospital of Soochow University, Suzhou, China
2 The First Affliated Hospital of Soochow University, Suzhou, China
3 Tongji Hospital of Tongji University, Shanghai, China
4 The First Affliated Hospital of Soochow University, Suzhou, China
5 The First Affliated Hospital of Soochow University, Suzhou, China
6 Hexiaoduo Beijing Health Management Co.,Ltd, Beijing, China
7 Tongji Hospital of Tongji University, Shanghai, China
8 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
9 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
10 East China Normal University, Shanghai, China
11 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
12 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
13 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
14 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
15 East China Normal University, Shanghai, China
16 The First Affliated Hospital of Soochow University, Suzhou, China
17 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
18 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
19 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
20 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
21 Tongji Hospital of Tongji University, Shanghai, China
22 Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
23 The First Affliated Hospital of Soochow University, Suzhou, China
24 The First Affliated Hospital of Soochow University, Suzhou, China
ABSTRACT
Background
Conventional ex vivo personalized CAR-T cell manufacturing is hampered by high costs and limited accessibility. Moreover, currently reported clinical studies of lentiviral vector–mediated in vivo CAR-T therapy have shown notable risks of severe cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). To address these challenges, we developed a novel lentiviral vector capable of generating in vivo IL-6–knockdown CD19 CAR-T cells with a validated safety profile. Preclinical studies have confirmed that this vector can specifically transduce T cells in mice, successfully generating CD19 CAR-T cells that effectively eliminate CD19+ tumor cells.
This phase I clinical trial (NCT07511426) was designed to evaluate the safety and preliminary efficacy of this novel lentiviral vector for in vivo generation of IL-6–knockdown CD19 CAR-T cells in patients with relapsed/refractory B-cell malignancies.
Methods
Three patients with B-cell malignancies (2 male, 1 female; 2 with diffuse large B-cell lymphoma and 1 with B-lymphoblastic lymphoma) have been enrolled, all having received ≥2 prior lines of therapy. Patients received a single intravenous infusion of the lentiviral vector without lymphodepleting chemotherapy.
Results
No CRS or ICANS of any grade was observed in any of the three patients, and no serious adverse events (SAEs) were reported. The best objective response rate (ORR) was 100% (3/3), with 2 patients achieving partial remission (PR) and 1 achieving complete remission (CR).
Notably, Patient 3 had stage IV DLBCL with dual expression and BCL2 rearrangement, who had received three prior lines of chemotherapy. Baseline PET-CT showed a right axillary lesion measuring 3.18×2.8 cm with SUVmax of 29.68. At 1 month post-infusion, follow-up PET-CT revealed lesion shrinkage to 1.7×1.2 cm with SUVmax decreasing to 4.71, demonstrating marked reduction in size and metabolic activity, and the response was assessed as PR.
Successful transduction and expansion of CAR-T cells in vivo were confirmed by qPCR detection following lentiviral vector infusion.
Conclusion
This preliminary study demonstrates that the novel lentiviral vector for in vivo generation of IL-6-knockdown CD19 CAR-T cells exhibits promising safety and efficacy in the treatment of B-cell malignancies.
DISCLOSURES
Changju Qu: No relevant conflicts of interest to declare.